Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients

  • Authors:
    • Youngil Koh
    • Dae-Young Kim
    • Sung-Hyo Park
    • Hyang-Min Byun
    • Inho Kim
    • Sung-Soo Yoon
    • Byoung Kook Kim
    • Eunkyung Park
    • Allen s. Yang
    • Seonyang Park
  • View Affiliations

  • Published online on: November 23, 2010     https://doi.org/10.3892/ol.2010.208
  • Pages: 181-187
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To define the correlation between BCR promoter DNA methylation and response to imatinib in chronic myeloid leukemia (CML), we investigated BCR promoter DNA methylation in three groups of subjects. The first group included chronic phase patients enrolled in an imatinib dose escalation trial. In the trial, patients who failed to achieve optimal response with 400 mg/day (suboptimal responders) received an escalated imatinib dose. The level of BCR promoter DNA methylation was quantitated at baseline six months after dose escalation. The second group included patients who achieved complete cytogenetic remission after receiving 400 mg/day of imatinib (optimal responders), and the third group were the healthy controls. In the suboptimal responders, an increased BCR promoter DNA methylation at six months compared with the baseline was related to a rapid reduction in the BCR-ABL/ABL transcript level following dose escalation (p=0.001) and a longer time to treatment failure (TTFx) of the dose-escalated imatinib (p=0.008). When multivariate analysis was performed with regard to the baseline BCR-ABL transcript level, baseline BCR promoter DNA methylation, and a change in the BCR promoter DNA methylation following dose escalation, the increase in the BCR promoter DNA methylation following dose escalation was an independent predictive factor for TTFx of dose-escalated imatinib (hazard ratio, 0.294; p=0.015). The baseline BCR promoter DNA methylation level in the suboptimal responders was lower than that in BCR promoter DNA methylation in the optimal responders (p=0.001) and healthy controls (p<0.001). In both the optimal and suboptimal responders, BCR promoter DNA methylation had an inverse correlation with the duration of the 400 mg/day imatinib use. In conclusion, increased BCR promoter DNA methylation strongly correlates with a more favorable imatinib response in CML patients.
View Figures
View References

Related Articles

Journal Cover

January-February 2011
Volume 2 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Koh Y, Kim D, Park S, Byun H, Kim I, Yoon S, Kim BK, Park E, Yang A , Park S, Park S, et al: Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients. Oncol Lett 2: 181-187, 2011
APA
Koh, Y., Kim, D., Park, S., Byun, H., Kim, I., Yoon, S. ... Park, S. (2011). Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients. Oncology Letters, 2, 181-187. https://doi.org/10.3892/ol.2010.208
MLA
Koh, Y., Kim, D., Park, S., Byun, H., Kim, I., Yoon, S., Kim, B. K., Park, E., Yang, A. ., Park, S."Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients". Oncology Letters 2.1 (2011): 181-187.
Chicago
Koh, Y., Kim, D., Park, S., Byun, H., Kim, I., Yoon, S., Kim, B. K., Park, E., Yang, A. ., Park, S."Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients". Oncology Letters 2, no. 1 (2011): 181-187. https://doi.org/10.3892/ol.2010.208